The Boston Herald
Monday, May 18, 2009

Eli Lilly & Co. has agreed to pay nearly $22.5 million to the Massachusetts Medicaid program to resolve allegations that the company engaged in the improper marketing of its antipsychotic drug, Zyprexa, according to the Massachusetts Attorney General’s Office.

The Massachusetts payment is part of a national settlement that has returned more than $700 million to Medicaid programs nationwide and an additional $65 million to other federal health care programs. Attorney General Martha Coakley’s office served as the lead representative and negotiator for a coalition representing 36 states and the District of Columbia.

Comments (1)
KevinH
Getting money back is good but if leading executives at Eli Lilly intentionally covered up the diabetes side effect of Zyprexa, shouldn’t they be criminally prosecuted for intentionally harming and even killing people?